论文部分内容阅读
Non-Hodgkins lymphoma (NHL) is a heterogeneous class of cancers.Even though completeresponse rates of 40-50% with chemotherapy can be attained, a substantial proportionof patients relapse, resulting in 3-year overall survival rates of about 30%.